Advances in the Treatment of Neurodegeneration

Cambridge New Therapeutics Forum (CamNTF)

This event will focus on cutting-edge strategies for developing and validating new therapies for Parkinson's disease.

School of Clinical Medicine

Agenda

Welcome 

Dr Nat Hastings has background in clinical neurosciences and bioengineering at the University of Cambridge. She established "Cellestial Health" to spin-out academic IP and develop new disease-modifying drugs for Parkinson's and other neurological conditions. She raised over £1M in academic and commercial grants plus equity funding to advance the translational developments.

Validating a novel drug target in Parkinson's: where to begin?

Simon leads on fostering promising new lines of research, promoting beneficial worldwide scientific and clinical collaborations across the community. Simon plays  a leading role in the ongoing growth of Cure Parkinson’s International Linked Clinical Trials (iLCT) programme, working alongside the iLCT Committee to ensure the most promising drugs are prioritised for clinical trial in Parkinson’s.

Developing a new therapy - understanding positioning: case study in Parkinson'

Dr Julia Greenland is a neurology registrar working in Addenbrooke's Hospital, Cambridge, UK. She trained in Newcastle-upon-Tyne, graduating in 2011. She completed her training in general medicine, and since 2016 has worked as a specialty registrar in neurology in the East of England. She has had an interest in Parkinson's disease since undergraduate training, undertaking an intercalated research masters degree with a clinical project orientated around the interaction of cognition and gait in Parkinson’s disease. She completed her PhD in 2024, which explored the role of the immune system in Parkinson’s disease. She was the sub-investigator of AZA-PD, a clinical trial of azathioprine in early Parkinson’s disease, and was involved in the design, set-up, running and analysis of this early phase randomised double-blind placebo-controlled trial.

Immunosuppression for Parkinson's disease?: Learning points from AZA-PD

Jonathan completed his PhD in the lab of Professor Will McEwan, where he developed genetically encoded degraders to selectively target and remove pathological aggregated tau protein from within living cells.
These degraders utilise the catalytic domain of the E3 ubiquitin ligase TRIM21 and demonstrated for the first time that pre-formed tau protein aggregates can be degraded via the TRIM21 pathway.


Aggregation State Selective Protein Degradation: A Novel Therapeutic Modality 

Drinks, buffet & networking

Our {communityGuidelinesLink} describe the sort of content we prohibit on Eventbrite. If you suspect an event may be in violation, you can report it to us so we can investigate.

To report other categories of prohibited or illegal content, submit {link}

Advances in the Treatment of Neurodegeneration

Good to know

Location

School of Clinical Medicine

How do you want to get there?

Agenda

Welcome

Validating a novel drug target in Parkinson's: where to begin?

Developing a new therapy - understanding positioning: case study in Parkinson'